Merit Medical Systems, Inc’s recent filing unveils that its CHIEF OPERATING OFFICER Peterson Neil W. unloaded Company’s shares for reported $0.45 million on Jan 06 ’26. In the deal valued at $90.00 per share,5,000 shares were sold. As a result of this transaction, Peterson Neil W. now holds 28,369 shares worth roughly $2.3 million.
Then, NEIL W PETERSON bought 5,000 shares, generating $450,000 in total proceeds.
Before that, Lampropoulos Fred P. sold 10,000 shares. Merit Medical Systems, Inc shares valued at $880,377 were divested by the Executive Chairman at a price of $88.04 per share. As a result of the transaction, Lampropoulos Fred P. now holds 1,019,955 shares, worth roughly $82.7 million.
JP Morgan initiated its Merit Medical Systems, Inc [MMSI] rating to an Overweight in a research note published on March 28, 2025; the price target was $120. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in mid December from “an Equal weight” to “an Overweight”. Robert W. Baird began covering MMSI with “an Outperform” recommendation on June 28, 2024. CL King started covering the stock on April 11, 2024. It rated MMSI as “a Buy”.
Price Performance Review of MMSI
On Tuesday, Merit Medical Systems, Inc [NASDAQ:MMSI] saw its stock fall -2.61% to $81.08. Over the last five days, the stock has lost -12.85%. Merit Medical Systems, Inc shares have fallen nearly -15.68% since the year began. Nevertheless, the stocks have fallen -8.01% over the past one year.
How much short interest is there in Merit Medical Systems, Inc?
A steep rise in short interest was recorded in Merit Medical Systems, Inc stocks on 2025-12-31, growing by 0.75 million shares to a total of 3.98 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 3.23 million shares. There was a rise of 18.78%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 07, 2024 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $87 price target.
